Inclusion Criteria:

- More than 18 years of age

- Patients who underwent pelvic lymph node dissection

- Patients with suspicious pelvic cancer who finished active treatments such as
chemotherapy, radiotherapy or surgery. The interval between the time of randomization
and the end of the treatment should be more than 2 weeks.

- The patient is able to understand the study and is willing to give written informed
consent to the study

- patient with edema-related symptoms such as leg heaviness, distension, tightness,
pain, limited movement, or weakness etc.

Exclusion Criteria:

- Severe systemic diseases causing peripheral edema, including renal disease

- Severe or uncontrolled cardiopulmonary disease, including implantable device such as
a pacemaker

- Acute superficial or deep vein thrombosis

- Previous major surgery for lower extremities, including metallic surgical implant

- Local infection in the lower extremities

- Auto-immunological disorders or vasculitis

- Use of systemic corticosteroids

- Pregnant or currently breastfeeding

- Alcohol or drug abuse

- Uncontrolled diabetes